Leading radiosurgery systems maker
) recently reported that medical practitioners at the University of
California, San Francisco ("UCSF") Helen Diller Family
Comprehensive Cancer Center have started to treat patients with its
popular TomoTherapy Systems. The latest addition has enabled the
center to offer more dynamic and effective cancer treatment,
enhancing patient outcomes.
The UCSF installed its first 3D image-guided, intensity
modulated radiation therapy ("IG-IMRT"), TomoTherapy System last
month. The center also uses Accuray's CyberKnife Robotic
Radiosurgery System along with other equipments to provide a
complete range of cancer care technologies.
The TomoTherapy Systems are unique fully integrated and advanced
radiation therapy systems used for treating all types of cancers.
It provides precise and safe radiation therapy by combining
computed tomography ("CT") imaging and radiation treatment delivery
in a single device, thereby lowering side effects.
Accuray is a global leader in the field of radiosurgery and
provides a non-surgical treatment option for patients diagnosed
with cancer. Most of the company's growth comes from acquiring
market share from its rivals for two of its flagship products, the
Cyberknife and the TomoTherapy Systems.
The company acquired Wisconsin-based radiation system maker
TomoTherapy in June 2011. The acquisition has bolstered Accuray's
foothold in the radiation oncology space. The merger marked the
union of TomoTherapy's unique radiation therapies and Accuray's
popular radiosurgery systems to create a leading player in this
market. The combined entity is now offering state-of-the-art
therapies, ranging from high-precision radiosurgery to image-guided
intensity-modulated radiation therapy for treating cancer and other
Accuray installed 22 new CyberKnife and TomoTherapy systems
during the most recent quarter, taking the aggregate global
installed base to 635 units. The company added $64.2 million of new
system orders in the quarter, leading to a total system backlog of
However, Accuray remains susceptible to reimbursement
uncertainties and faces stiff challenges from competitive product
). We currently have a Neutral recommendation on the stock, which
is backed by a short-term Zacks #3 Rank (Hold).
ACCURAY INC (ARAY): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.